Lilly Now Sees Obesity Pill Approval as Early as Second Quarter

Eli Lilly & Co. has adjusted its timeline for the U.S. approval of its obesity pill, now expecting a decision as early as the second quarter of 2026. Previously, the company had indicated approval could come by March. The pill, known as orforglipron, is part of the growing GLP-1 class of medications used to treat obesity and diabetes according to Bloomberg.

The obesity pill market has quickly evolved as patients and healthcare providers seek alternatives to injectable treatments. Novo Nordisk recently secured FDA approval for its Wegovy pill, a key development in the GLP-1 space. This market shift highlights the growing demand for more convenient and potentially cheaper oral options.

Eli Lilly's pill has been granted a fast-track review by the FDA, indicating regulatory urgency in approving the drug. If approved, the lowest dose of the pill will cost $149 a month, according to the company. This pricing could make the treatment more accessible to some patients compared to current injectable options.

Why Did This Happen?

The delay in approval reflects the complexity of navigating the regulatory landscape for a new drug in a competitive market. Eli Lilly's CFO, Lucas Montarce, emphasized that the pill is still on track for a Q2 2026 timeline. This adjustment does not signal any major setbacks in the drug's development.

The GLP-1 market has been dominated by injectable treatments like Wegovy and Zepbound. However, the introduction of oral alternatives is expected to expand the market significantly. These pills offer a more patient-friendly option and may attract individuals who have been hesitant to use injections.

How Did Markets Respond?

The obesity pill market is already showing signs of expansion. Novo Nordisk's Wegovy pill has been available to patients since late 2025 and is priced at $149 to $299 per month, depending on the dose. While the pills do not offer more weight loss than injectable options, they may attract new patients who are needle-averse or looking for a more convenient treatment option.

Analysts suggest that the pill market could capture around 24% of the global weight-loss drug market by 2030, according to a Goldman Sachs report from August 2025. This projection assumes that the pills will attract new patients who have not previously considered GLP-1 treatments.

What Are Analysts Watching Next?

Market dynamics may shift as more players enter the GLP-1 space. Eli Lilly is not the only company developing a pill. Competitors like Novo Nordisk, Pfizer, and AstraZeneca are also working on their own oral treatments. Structure Therapeutics, for example, has shown promising results with its aleniglipron pill, which helped patients lose more than 11% of their body weight in midstage trials.

Insurance coverage remains a critical factor in the pill's success. While direct-to-consumer pricing is lower than for injections, many employers have been reluctant to cover GLP-1 treatments due to their high costs. Analysts suggest that the pill may not significantly change insurance coverage patterns, but it could still attract patients willing to pay out of pocket.

Eli Lilly's CFO also noted that a multidose pen of its weight-loss drug Zepbound is expected to be approved in the coming months. This development could further expand the company's footprint in the GLP-1 market.

Investors should closely monitor the FDA's decision on orforglipron and how quickly the pill gains market traction. Given the high demand for GLP-1 treatments, a successful launch could have significant implications for Eli Lilly's revenue and market position.